Buentzel, J., Micke, O., Adamietz, I.A., Monnier, A., Glatzel, M., & deVries, A. (2006). Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III study. International Journal of Radiation Oncology, Biology, Physics, 64, 684–691.
To evaluate the efficacy and safety of IV amifostine during radiochemotherapy for head-and-neck cancer
Patients in the study group received 300 mg/m2 IV amifostine on the days in which they received carboplatin and radiation therapy (RT). On the days in which they received only RT, they were given 200 mg/m2 IV amifostine.
The study was conducted between October 1996 and October 1999.
The intervention was not found to be effective in the management of mucositis toxicity.
This was the first randomized and placebo-controlled study of amifostine in the head and neck cancer population.